On air · 2 of 3 networks
Dyne Therapeutics
- dyne-tx.com
- Healthcare & Life Sciences
- US
- 330 employees
Dyne Therapeutics’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 22. Watch Dyne Therapeutics with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 22 | Checked 30 Oct 2026 | See all 22 ads → | ||
| Meta | Running | 24 | Active ads on the Meta Ad Library, all countries | Checked 27 Oct 2026 | Collect them with the API → |
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 27 Oct 2026 | Collect them with the API → |
Dyne Therapeutics has 22 live LinkedIn ads. Its Facebook page had 24 active ads on 27 Oct 2026, and we recorded no Google ads on 27 Oct 2026.
Latest ads
- LINKEDIN · IMAGERecorded 18 Oct 2026
Our understanding of dystrophin continues to evolve. This new equation introduces a more expansive way of thinking: one that considers 3 key components of this essential structural protein simultaneously and how functional improvement may be achieved in Duchenne muscular dystrophy (DMD). See how a new equation of dystrophin could shift the focus from slowing progression to improving function.
- LINKEDIN · CAROUSELRecorded 18 Oct 2026
A deeper examination of dystrophin suggests 3 key components critical to driving meaningful functional improvement in Duchenne muscular dystrophy (DMD). See how enhanced dystrophin production could strengthen muscle integrity.
- LINKEDIN · VIDEORecorded 16 Sept 2026
Hear Dr Finanger explain how the focus on dystrophin has expanded to 3 key components: quantity, quality, and distribution. Achieving all 3 simultaneously could add up in ways that matter most to people living with Duchenne muscular dystrophy (DMD). Explore what it could mean to solve the equation for function in DMD.
- LINKEDIN · IMAGERecorded 16 Sept 2026
Our understanding of dystrophin continues to evolve. It now points to a more expansive way of thinking: one that considers 3 key components of this essential structural protein simultaneously and how functional improvement may be achieved in Duchenne muscular dystrophy (DMD). See how a new equation of dystrophin could shift the focus from slowing progression to improving function.
- LINKEDIN · IMAGERecorded 16 Sept 2026
Myotonic dystrophy type 1 (DM1) is a rare, progressive, genetic, neuromuscular disease affecting skeletal, smooth, and cardiac muscle, as well as the eyes, heart, endocrine system, and central nervous system. Dyne is committed to advancing treatment for people living with DM1 and other neuromuscular diseases by developing investigational medicines with a targeted delivery mechanism to potentially provide functional improvement.* Learn more. *Dyne’s investigational medicine for DM1 has not been approved as safe or effective by any regulatory authority.
- LINKEDIN · FOLLOWRecorded 16 Sept 2026
Get the latest jobs and industry news
6 of 22 adsSign up to see every Dyne Therapeutics ad, filter by format and date, and get alerts on new ones.
See all 22 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.